Actively Recruiting
Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder
Led by Nader Pouratian · Updated on 2026-05-05
10
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if deep brain stimulation (DBS) works to treat refractory obsessive-compulsive disorder (OCD). The main questions it aims to answer are: * Assess the effects of the anteromedial sub-thalamic nucleus (amSTN)stimulation on obsessive/compulsive symptoms. * Map the amSTN using neuronal responses \[single unit and local field potentials (LFP) recordings\] at rest and under high frequency stimulation during surgery. * Record chronic brain activity with the implanted pulse generator and look for neuronal signatures correlated with symptom severity. Researchers will compare active deep brain stimulation to a placebo (sham stimulation) to see if DBS works to treat refractory OCD. Participants will: * Undergo surgery for the implantation of a deep brain stimulation device * Follow-up visits every three weeks with study staff * 6 month follow-up for the next 2-3 years after first year of study participation is complete
CONDITIONS
Official Title
Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of obsessive-compulsive disorder (OCD) according to DSM-5 criteria
- Severe OCD with Yale-Brown Obsessive-Compulsive Scale (YBOCS) score over 27
- Refractory OCD with severe symptoms and impairment for more than 5 years despite pharmacological and psychological treatments
- Failure to improve after treatment with at least two serotonin transport inhibitors and one augmenting agent for adequate periods
- Failure to improve despite adequate cognitive behavioral therapy as evaluated by study psychiatrist
- Age between 22 and 75 years
- Ability to understand and sign written informed consent
You will not qualify if you...
- Diagnosis of severe major depressive disorder with psychotic features
- Significant suicidal risk (Hamilton Depression scale item 3 >2)
- Comorbidity with primary psychotic disorder, post-traumatic stress disorder, or eating disorder
- History of substance or alcohol dependence or abuse in the past 12 months
- Significant cognitive decline (MMSE <26 and MoCA <24)
- Other clinically significant neurological or medical illness affecting brain function (except tic disorder)
- Clinically significant abnormality on preoperative MRI affecting surgical safety
- Any contraindications to DBS, infections, coagulopathy, significant cardiac or other surgical risk factors
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
Actively Recruiting
Research Team
N
Nader Pouratian, M.D., Ph.D.
CONTACT
T
Tash Mupambo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here